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DrDavid R. Jones (Charlottesville, Va). I have only a few ques-
tions for you. You looked only at protein levels of the MMPs. Can
you say what you perceive are some of the pitfalls of looking at
these in isolation in a small sample size, and do you believe that per-
haps looking at messenger RNA levels would add some value to
your analysis?990 The Journal of Thoracic and Cardiovascular SurgDr Shah. Thank you for your question. Yes, we acknowledge
that we do have a small sample size, but our assay is very sensitive
and highly quantifiable even in small samples, as we have previ-
ously shown in cardiovascular studies. We decided to look at the
protein because it is the final effector and, therefore, our focus.
Dr Jones. Second, several groups have shown that MMP-9
levels are predictive of recurrence, much as you have seen here.
I found it interesting that there was no difference in MMP-9 levels
between your normal and your cancerous lung tissue. Do you have
a possible explanation for that?
Dr Shah. The difference may be that semiquantitative methods
were used in previous studies. It is also known that MMP may be
a marker of greater importance in more advanced NSCLC.
DrDaoM.Nguyen (Miami, Fla).You used a tumor homogenate.
It is a mixture of cells from the tumor itself and from the stroma. Are
the MMPs coming from the stroma, like tumor-derived stromal tis-
sues, or are they coming from the cancer cells themselves, or both?
Dr Shah. That is a good question. I honestly could not speculate.
I would assume they are coming from the tumor just because of the
difference between the tumor sample and the normal sample.
Dr Nguyen. It can come from both, actually. You should look
into it. I think laser-capture microdissection can help you with that.
Second question: This is a protein and these are enzymes. Are
you planning to do enzyme assays? A lot of these proteins are
present in small quantity and hard to detect. Do you plan to do
zymograms?
Dr Shah. Possibly in future studies, yes.ery c April 2010
